Susan Rotzinger, PhD

  • 4Articles
  • 28KReads
  • 2019–2023Active
  • 45Collaborators
  • 125Citations

About

Susan Rotzinger, PhD, is affiliated with the Department of Psychiatry at the University of Toronto, Canada. Her publications focus on major depressive disorder (MDD) and suicide, including studies on antidepressant treatment outcomes, prediction of response to escitalopram and aripiprazole augmentation, and the use of machine learning to predict quality of life improvements. Her work also examines clinical and molecular predictors of worsening suicidal ideation during treatment.

Publications

JCP
Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report
Original Research

Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report

November 15, 2023

Quality of life is an important patient-centric outcome. Using machine learning methods, this study found that quality of life improvement with antidepressant treatment can be predicted using early depression...
, , , et al
JCP
Original Research

Interest-Activity Levels and Need for AD Augmentation in MDD

June 16, 2020

Depressed people who have lost interest and are inactive may not respond well to antidepressants. This study examined whether depressed subjects with low interest and activity who responded poorly...
, , , et al
JCP
Original Research

Worsening of Suicidal Ideation During AD Treatment

May 7, 2019

Antidepressants are effective in preventing suicide, but some antidepressant-treated patients experience increased suicidal ideation. Read this article to learn if clinical features and biomarkers can predict worsened suicidal ideation...
, , , et al
JCP
Original Research

CAN-BIND-1 Outcomes and Early Response Prediction in MDD

February 5, 2019

Antidepressant medications are often prescribed with little certainty about their potential effectiveness in individual patients. Can early symptom reduction help predict later symptomatic and functional outcomes of antidepressant treatment?...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe